12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

GT038 regulatory update

Genable said FDA granted Orphan Drug designation for GT038 to treat retinitis pigmentosa. Genable plans to start clinical testing...

Read the full 73 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >